Search results
Pharma M&A: The top high value deals in 2023
Pharmaceutical Technology· 6 days agoFrom Pfizer’s Seagen acquisition to Sanofi’s deal with Provention Bio, Pharmaceutical Technology lists the highest value pharma mergers and acquisitions...
Women with a common hormonal disorder have few good treatment options. Could GLP-1 drugs help?
BioPharma Dive· 6 days agoThe spokesperson added that Novo has “not conducted studies to assess the efficacy and safety of our...
Semafor Business Summit: Beware of the the mushy middle
Semafor· 6 days agoCue a $4 billion cost-cutting effort. We also talked about the weight-loss craze, where Pfizer is...
Novo to spend $4B on US plant, adding to obesity drug production push
BioPharma Dive· 6 days agoThe planned facility in North Carolina is Novo’s latest multibillion-dollar investment in the...
This weekend in Bloomington: Adult Field Day, Bubble Fest, punk music celebration
The Herald-Times· 5 days agoGrab lawn chairs and blankets to enjoy a picnic while Pendreigh performs. Pendreigh, whose music has...
Centre Approves Rs 700 Crore To Set Up Institutes Of Pharma, Medical Technology
NDTV· 3 days agoThe Central government has earmarked Rs 700 crore to set up centres of excellence at the National...
Israel’s Leviathan field primed for expansion, more gas exports approved
Offshore Technology· 6 days agoThe Middle East nation, currently involved in bitter fighting in Gaza, is looking to boost its...
Where US stock market is headed after wild first half: 5 charts
The Economic Times· 2 days agoA boom in artificial intelligence fueled a blistering first half for the US stock market, and...
India to make Ozempic-like drugs for diabetes, obesity under PLI by 2026
Business Standard India· 4 days agoPopular peptide drugs for diabetes and obesity — Glucagon-like peptide receptor agonist (GLP-1RA) —...
The rise and fall of America's most ambitious sports media company
The Ada News, Okla.· 3 days agoJun. 28—Berry Tramel is not a man who makes rash decisions. But he had taken a risky leap. Last September, following more than three decades at The Oklahoman, the legendary sports reporter quit ...